Agenus to Present Botensilimab Data at a Plenary Session of the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05 2022 - 8:00AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of therapeutics designed to activate the immune
response to cancers and infections, today announced the Company
will present new data on its growing portfolio of clinical-stage
immuno-oncology programs at the Society for Immunotherapy of Cancer
(SITC) 37th Annual Meeting, to be held November 8-12 in Boston, MA
and virtually.
New data on multiple expansion cohorts from the Phase 1 study of
botensilimab (a multifunctional Fc-enhanced anti-CTLA-4) in cold
(immunotherapy-resistant) tumors will be presented at an oral
plenary session on novel immunotherapies on Saturday, November 12th
at 10:50am ET. Three additional presentations will include new data
on the mechanisms underpinning botensilimab’s differentiated and
enhanced anti-tumor immunity and provide an overview of the Phase 2
trial in progress of AGEN1423, an anti-CD73-TGFβ-trap bifunctional
antibody in combination with balstilimab (anti-PD-1) in advanced
pancreatic cancer.
Separately, Agenus announced today that Dhan Chand, PhD, Head of
Drug Discovery at Agenus was selected to present on the topic of
enhanced CTLA-4 blockade at the SITC Targets for Cancer IO Deep
Dive Series on Wednesday, October 5, from 2:00 pm – 4:00 pm ET. To
register for the webinar, please visit the Educational and
Scientific Programs section of the SITC website. Dr. Chand’s
selection to participate through a highly competitive process
underscores his leadership and highlights the focus on
botensilimab, as well as the field’s appreciation for the important
role CTLA-4 plays in anti-tumor immunity and the scientific
contributions and understanding advanced by the team at Agenus.
Presentation Details:
Abstract Title: Botensilimab, a
Novel Innate/Adaptive Immune Activator, plus or minus Balstilimab
(Anti-PD-1) in “Cold” and I-O Refractory Metastatic Solid Tumors
(NCT03860272)Abstract Number:
778Presenting Author: Breelyn Wilky, MD, Director
of Sarcoma Medical Oncology, Deputy Associate Director for Clinical
Research, University of Colorado MedicineDetails:
Session 302: Thomas Waldmann Memorial Plenary Session: New
Immunotherapies, 11/12/2022, 9:55am – 11:25am ET
Abstract Title: Botensilimab,
an Fc-enhanced CTLA-4 Antibody, Enhances Innate and Adaptive Immune
Activation to Promote Superior Anti-Tumor Immunity in “Cold” and
I-O Refractory TumorsAbstract Number:
470Presenting Author: Daniel Levey, PhD, Senior
Director Vaccine Research, AgenusDetails: Poster
Hall, 11/10/2022 – 11/11/2022, 9:00am – 9:00pm ET
Abstract Title: Botensilimab
Modulates Innate and Adaptive Gene Expression Programs Resulting in
Superior Immune Stimulation Relative to a First-Generation
Anti-CTLA-4 AntibodyAbstract Number:
941Presenting Authors: Shanmugarajan Krishnan,
PhD, Vision Scientist II, Agenus; Jacky Chow, PhD, Senior
Scientist, AgenusDetails: Poster Hall, 11/10/2022
– 11/11/2022, 9:00am – 9:00pm ET
Abstract Title: Phase 2 trial
of AGEN1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, in
Combination with Balstilimab, with or without Chemotherapy in
Subjects with Advanced Pancreatic CancerAbstract
Number: 651Presenting Author: Bruno
Bockorny, MD, Assistant Professor, Medicine, Harvard Medical
SchoolDetails: Poster Hall, 11/10/2022 –
11/11/2022, 9:00am – 9:00pm ET
Complete abstracts will be released on Monday, November 7, 2022
at 8:00am ET. Updated data presented at the conference will be
available to view in the Publications section of the Agenus website
(https://agenusbio.com/publications) following the SITC Annual
Meeting.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and our
Twitter handle @agenus_bio. Information that may be important to
investors will be routinely posted on our website and Twitter.
Forward Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements relating to the use of botensilimab, for instance,
statements regarding therapeutic benefit and efficacy, mechanism of
action (including validation of mechanism of action), potency,
durability, and safety profile (including the absence of specific
toxicities) of the Company’s therapeutic candidates, both alone and
in combination with each other and/or other agents (e.g.,
botensilimab and/or balstilimab in combination); and any other
statements containing the words "may," "believes," "expects,"
"anticipates," "hopes," "intends," "plans," "forecasts,"
"estimates," "will," “establish,” “potential,” “superiority,” “best
in class,” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactEthan LovellChief Corporate Affairs
& Communications
Officer339-927-1763ethan.lovell@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024